Antibody-drug conjugate therapies in multiple myeloma-what's next on the horizon?

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Targeted immunotherapy, particularly antibody-drug conjugates (ADCs), has become a significant advancement in cancer care.
• ADCs utilize a monoclonal antibody to target tumor cells, delivering a cytotoxic payload directly to cancer cells for precise cancer treatment.
• Multiple myeloma (MM) is a challenging hematologic malignancy with limited curative options.

Purpose of the Study:

• To review current antibody-drug conjugates (ADCs) undergoing clinical trials for multiple myeloma (MM).
• To identify promising ADCs that may represent the next wave of FDA-approved treatments for MM.
• To provide an overview of the evolving landscape of ADC-based therapies in MM treatment.

Main Methods:

• Literature review of ongoing clinical trials evaluating ADCs in multiple myeloma.
• Analysis of the mechanisms of action and clinical data for selected ADCs.
• Focus on ADCs demonstrating significant promise for future regulatory approval.

Main Results:

• Belantamab mafodotin is the first-in-class ADC approved by the FDA for MM treatment.
• Several other ADCs are in various phases of clinical trials for MM, showing potential efficacy.
• The review highlights specific ADCs with promising profiles for subsequent FDA evaluation.

Conclusions:

• ADCs represent a rapidly advancing therapeutic strategy for multiple myeloma.
• Ongoing clinical trials are crucial for developing next-generation ADCs for MM.
• The future of MM treatment is increasingly influenced by targeted ADC therapies.